My bet would be that they'll continue to look at new genes. And I wouldn't be surprised to see them continue to look at illnesses that fall under they same FDA department as PMS and Pitt Hopkins.
But I think that's their fallback option.
I would like to have heard of what percentage of effort is being placed into the new indications.
My guess would be less than 5% of total company effort right now.
Pipeline-in-a-drug, page-4
-
- There are more pages in this discussion • 184 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
0.000(0.00%) |
Mkt cap ! $2.552B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.97 | $19.69 | $4.156M | 209.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 246 | $19.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.99 | 512 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |